Abstract:The Philadelphia chromosome is formed by a balanced, reciprocal translocation that pairs sequences from BCR on Chromosome 22 with sequences from ABL on Chromosome 9, resulting in the production of the constitutively active tyrosine kinase (TK) BCR-ABL. Depending on the location of the breakpoint within BCR, three different sizes of BCR-ABL may form, each associated with distinct clinical sequelae. Previous studies identified a functional domain within the BCR sequences preserved by the more-indolent forms of BCR-ABL (i.e., p210 and p230) that demonstrates a constitutive Rho guanine nucleotide exchange factor (RhoGEF) activity. Using the structurally derived S509A mutation, which does not affect TK activity but abrogates RhoGEF signaling, we, subsequently, showed that this feature regulates leukemia progression in mice. The RhoGEF domain was recently reported to contain two missense mutations (F547L and T654K) in a chronic myelogenous leukemia (CML) blast crisis (BC) patient, suggesting that it may play a role in human disease as well. To evaluate the clinical significance of this region, we, therefore, examined p210 BCR-ABL constructs containing these clinically derived RhoGEF mutations (CDRMs), both in isolation and in combination, using a murine bone marrow transplant (mBMT) model of CML. The mutations did not destabilize p210 BCR-ABL expression or TK activity but decreased RhoGEF signaling. Relative to mice transplanted with wild-type (WT) p210 BCR-ABL, those that received the CDRMs exhibited an earlier onset of disease, frequently developing previously unseen dermatologic involvement or myeloid sarcomas, but demonstrated significantly increased survival in an additive manner [Fig. 1]. While mice transplanted with WT p210 BCR-ABL exhibited neutrophilia that progresses to a less-differentiated phenotype at death, disease in the CDRM mice was characterized by eosinophilia and monocytosis with no maturation arrest. The most likely cause of death in mice transplanted with WT p210 BCR-ABL is widespread hematogenous involvement of the lungs resulting in acute respiratory distress. In contrast, mice receiving the CDRMs demonstrated pulmonary involvement which was limited to the bronchovascular bundles or subpleural space. This is consistent with a switch to lymphatogenous spread, likely secondary to skewed differentiation, and it implies an alternate cause(s) of death. To help determine the mechanism responsible for the observed differences in differentiation and maturation arrest, we next studied the CDRMs in vitro using the 32Dcl3 murine myeloid precursor cell line. A growing body of evidence suggests that the DNA damage response can affect lineage restriction in myeloid cells; it is also well-established that the accumulation of DNA damage is necessary for progression to BC. Accordingly, the CDRMs were associated with the restoration of p53 activation and the G1/S cell cycle checkpoint relative to WT p210 BCR-ABL. This suggests that the RhoGEF domain may be responsible for the suppression of the DNA damage response. Because the mBMT phenotype associated with the S509A mutation was distinct from that of the CDRMs, it may indicate that this capability is mediated by some functionality yet to be described. Importantly, the CDRMs were also associated with increased Src family kinase activity, which is thought to be a major mechanism of BCR-ABL-independent TK inhibitor resistance and minimal residual disease. Collectively, these results suggest that the BCR-ABL RhoGEF domain can influence disease progression and response to treatment in human leukemia. Disclosures No relevant conflicts of interest to declare.

978 CD44 Expression on Leukocytes is Dynamically Regulated by ECRG4

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

ECRG4 Acts As a Tumor Suppressor Gene Frequently Hypermethylated in Human Breast Cancer.

[Expression and Function of ECRG4 in Hepatocellular Carcinoma].

Chemokine CXCL4 interactions with extracellular matrix proteoglycans mediate widespread immune cell recruitment independent of chemokine receptors

Ecrg4 peptide is the ligand of multiple scavenger receptors

A potential role of human esophageal cancer-related gene-4 in cardiovascular homeostasis

The ECRG4 cleavage product augurin binds the endotoxin receptor and influences the innate immune response during otitis media

CD44v10 expression in the mouse and functional activity in delayed type hypersensitivity

Cd44v4 is A Major E-Selectin Ligand That Mediates Breast Cancer Cell Transendothelial Migration

Critical Role of CD55 in Controlling Wound Healing

Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress

Abstract 235: Interaction Between a Macrophage Chemokine Receptor, CCR2, and Its Ligand Plays a Crucial Role in Macrophage Recruitment Aand Regulated Inflammation in Normal Wound Healing

Chemokine ligand-receptor interactions critically regulate cutaneous wound healing

CD44 Potentiates Hepatocellular Carcinoma Migration and Extrahepatic Metastases Via the AKT/ERK Signaling CXCR4 Axis.

CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration

Expression of ECRG4, a Novel Esophageal Cancer-Related Gene, Downregulated by CpG Island Hypermethylation in Human Esophageal Squamous Cell Carcinoma

The Chemokine Receptors CXCR1 and CXCR2 Couple to Distinct G Protein-Coupled Receptor Kinases To Mediate and Regulate Leukocyte Functions

Physical interaction with Ephrin B1 promotes CXCR4 intracellular localization and oncogenic potential

Examination of Clinically-Derived p210 BCR/ABL Rhogef Mutations in a Murine Bone Marrow Transplantation Model of CML

CD44 is Associated with Poor Prognosis of Ccrcc and Facilitates Ccrcc Cell Migration and Invasion Through HAS1/MMP9.